European Heart Journal Advance Access originally published online on June 11, 2008
European Heart Journal 2008 29(15):1851-1857; doi:10.1093/eurheartj/ehn249
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The potential clinical utility of intravascular ultrasound guidance in patients undergoing percutaneous coronary intervention with drug-eluting stents
Division of Cardiology, Washington Hospital Center, 110 Irving Street, NW, Suite 4B-1, Washington, DC 20010, USA
Received 25 October 2007; revised 19 May 2008; accepted 22 May 2008; online publish-ahead-of-print 11 June 2008.
* Corresponding author. Tel: +1 202 877 2812, Fax: +1 202 877 2715, Email: ron.waksman{at}medstar.net
Aims: To assess the impact on clinical outcomes of intravascular ultrasound (IVUS) guidance during drug-eluting stent (DES) implantation. IVUS guidance during percutaneous coronary intervention (PCI) has been demonstrated to be useful in optimizing stent deployment. However, it is not proved that routine use of IVUS guidance with DES implantation can prevent stent thrombosis or restenosis.
Methods and results: The clinical outcomes of 884 patients undergoing IVUS-guided intracoronary DES implantation from April 2003 to May 2006 were compared with the outcomes of a propensity-score matched population undergoing DES implantation with angiographic guidance alone. The primary endpoint of the study was definite stent thrombosis at 12 months. The secondary endpoint was major adverse cardiac events (MACE). After propensity-score matching, the two groups were well matched for clinical and angiographic characteristics. Patients undergoing IVUS-guided DES implantation underwent less direct stenting, more post-dilation, and had greater cutting balloon and rotational atherectomy use. At 30 days and at 12 months, a higher rate of definite stent thrombosis was seen in the No IVUS group (0.5 vs. 1.4%; P = 0.046) and (0.7 vs. 2.0%; P = 0.014), respectively. There were no major differences in late stent thrombosis and MACE (14.5 vs. 16.2%; P = 0.33) at 12 month follow-up between the groups. Rates of death and Q-wave myocardial infarction were similar, and there was no significant difference between groups in target vessel revascularization. However, a trend was seen in favour of the IVUS group in target lesion revascularization (5.1 vs. 7.2%; P = 0.07). IVUS guidance was an independent predictor of freedom from cumulative stent thrombosis at 12 months (adjusted HR 0.5, CI 0.1–0.8; P = 0.02).
Conclusion: IVUS guidance during DES implantation has the potential to influence treatment strategy and reduce both DES thrombosis and the need for repeat revascularization.
Key Words: Intravascular ultrasound • Drug-eluting stent • Percutaneous coronary intervention
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. W. Stone and G. S. Mintz Unprotected Left Main Intervention: The Light at the End of the Tunnel? Circ Cardiovasc Intervent, June 1, 2009; 2(3): 156 - 158. [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Bhalla and H. V. Anderson Drug-Eluting Stents: Careful Deployment Required J. Am. Coll. Cardiol. Intv., May 1, 2009; 2(5): 435 - 436. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Price, D. E. Kandzari, and P. S. Teirstein Change We Can Believe In: The Hyper-Evolution of Percutaneous Coronary Intervention for Unprotected Left Main Disease With Drug-Eluting Stents Circ Cardiovasc Intervent, December 1, 2008; 1(3): 164 - 166. [Full Text] [PDF]
|
|
|
|
|
|
A. Colombo and R. T. Gerber Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Not Be Continued for More Than 1 Year and Preferably Indefinitely Circ Cardiovasc Intervent, December 1, 2008; 1(3): 226 - 232. [Full Text] [PDF]
|
|